Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright

Adicet Bio (NASDAQ:ACET)‘s stock had its “neutral” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports.

ACET has been the subject of several other research reports. Wedbush reissued an “outperform” rating and issued a $5.00 price objective on shares of Adicet Bio in a research note on Thursday, November 7th. StockNews.com downgraded shares of Adicet Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. Finally, JMP Securities reissued a “market perform” rating on shares of Adicet Bio in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $7.50.

Adicet Bio Trading Up 4.6 %

Shares of NASDAQ:ACET opened at $0.90 on Thursday. Adicet Bio has a 12 month low of $0.81 and a 12 month high of $2.54. The company has a 50-day moving average price of $0.94 and a 200 day moving average price of $1.17. The company has a market cap of $74.06 million, a price-to-earnings ratio of -0.53 and a beta of 1.86.

Institutional Trading of Adicet Bio

Institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its stake in shares of Adicet Bio by 10,321.9% during the third quarter. JPMorgan Chase & Co. now owns 80,353 shares of the company’s stock valued at $116,000 after acquiring an additional 79,582 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Adicet Bio by 14.5% during the third quarter. Geode Capital Management LLC now owns 768,566 shares of the company’s stock valued at $1,107,000 after acquiring an additional 97,567 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of Adicet Bio by 161.3% during the third quarter. GSA Capital Partners LLP now owns 39,208 shares of the company’s stock valued at $56,000 after acquiring an additional 24,203 shares in the last quarter. FMR LLC raised its stake in shares of Adicet Bio by 31.3% during the third quarter. FMR LLC now owns 276,169 shares of the company’s stock valued at $398,000 after acquiring an additional 65,903 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in shares of Adicet Bio by 12.5% during the third quarter. XTX Topco Ltd now owns 292,180 shares of the company’s stock valued at $421,000 after acquiring an additional 32,392 shares in the last quarter. Institutional investors own 83.89% of the company’s stock.

About Adicet Bio

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.